Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

FDA Approves Inluriyo Plus Verzenio for Breast Cancer

Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 19, 2026

Sentiment
15
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands Eli Lilly's oncology portfolio and provides a new combination regimen for a defined breast cancer population, supporting incremental revenue expectations for the company. It reinforces Lilly's competitive position in the oral SERD and CDK4/6 inhibitor space, though the immediate stock reaction was muted given the approval was widely anticipated.

pharmaceuticals biotechnology healthcare

Eli Lilly and Company announced that the U.S. United States — Food and Drug Administration granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in combination with Abemaciclib (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy. The approval is based on results from the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival to 11.1 months versus 5.5 months for Inluriyo alone, with a hazard ratio of 0.53. This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as monotherapy for the same patient population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for early-stage breast cancer, with more than 8,000 patients enrolled across 650+ sites in 30+ countries and initial results anticipated in 2027. The combination is now available in the United States. Eli Lilly shares closed Friday at $1,152.93, up $0.49 or 0.04%.

stock
Eli Lilly receives FDA full approval for Inluriyo plus Abemaciclib, expanding its oncology franchise and adding a new revenue stream. The approval strengthens its competitive position in breast cancer treatment.
Importance 95.0 Sentiment 25.0
govactor
The FDA granted full approval to the Inluriyo and Abemaciclib combination, enabling U.S. commercialization of the regimen.
Importance 70.0 Sentiment 5.0
oth
Abemaciclib gains an additional approved combination use, broadening its label and potential patient population in ESR1-mutated breast cancer.
Importance 60.0 Sentiment 15.0
cnt
The U.S. market is where the newly approved combination is now available, affecting domestic treatment options and healthcare spending.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.